Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 St.-Petersburg, Russia.
Department of Medical Genetics, St.-Petersburg Pediatric Medical University, 194100 St.-Petersburg, Russia.
Int J Mol Sci. 2023 Sep 17;24(18):14203. doi: 10.3390/ijms241814203.
The majority of , , and rearrangements result in increased expression of the kinase portion of the involved gene due to its fusion to an actively transcribed gene partner. Consequently, the analysis of 5'/3'-end expression imbalances is potentially capable of detecting the entire spectrum of gene fusions. Archival tumor specimens obtained from 8075 patients were subjected to manual dissection of tumor cells, DNA/RNA isolation, and cDNA synthesis. The 5'/3'-end expression imbalances in genes were analyzed by real-time PCR. Further identification of gene rearrangements was performed by variant-specific PCR for 44 common fusions, and, whenever necessary, by RNA-based next-generation sequencing (NGS). cDNA of sufficient quality was obtained in 7424/8075 (91.9%) tumors. rearrangements were detected in 7/6436 (0.1%) lung carcinomas, 11/137 (8.0%) pediatric tumors, and 13/851 (1.5%) adult non-lung malignancies. The highest incidence of translocations was observed in pediatric sarcomas (7/39, 17.9%). Increased frequency of fusions was seen in microsatellite-unstable colorectal tumors (6/48, 12.5%), salivary gland carcinomas (5/93, 5.4%), and sarcomas (7/143, 4.9%). None of the 1293 lung carcinomas with driver alterations in oncogenes had 5'/3'-end expression imbalances. Variant-specific PCR was performed for 744 tumors with a normal 5'/3'-end expression ratio: there were no rearrangements in 172 -negative lung cancers and 125 pediatric tumors, while fusions were detected in 2/447 (0.5%) non-lung adult malignancies. In conclusion, this study describes a diagnostic pipeline that can be used as a cost-efficient alternative to conventional methods of analysis.
大多数 、 和 重排导致相关基因激酶部分的表达增加,因为它与一个活跃转录的基因伴侣融合。因此,分析 5'/3'-末端表达失衡有可能检测到整个 基因融合谱。从 8075 名患者中获得存档的肿瘤标本,进行肿瘤细胞的手动解剖、DNA/RNA 分离和 cDNA 合成。通过实时 PCR 分析 基因的 5'/3'-末端表达失衡。通过针对 44 种常见 融合的变体特异性 PCR 进一步鉴定基因重排,并在必要时通过基于 RNA 的下一代测序 (NGS) 进行鉴定。在 7424/8075(91.9%)肿瘤中获得了足够质量的 cDNA。在 7/6436(0.1%)肺癌、11/137(8.0%)儿科肿瘤和 13/851(1.5%)成人非肺癌恶性肿瘤中检测到 重排。儿科肉瘤中观察到 易位的最高发生率(7/39,17.9%)。在不稳定微卫星的结直肠肿瘤(6/48,12.5%)、唾液腺癌(5/93,5.4%)和肉瘤(7/143,4.9%)中观察到 融合的频率增加。在 1293 例具有 驱动基因改变的肺癌中,没有 5'/3'-末端表达失衡。对 744 例具有正常 5'/3'-末端表达比的肿瘤进行了变体特异性 PCR:在 172 例阴性肺癌和 125 例儿科肿瘤中没有重排,而在 447 例非肺癌成人恶性肿瘤中有 2 例检测到融合。总之,本研究描述了一种诊断管道,可作为传统 分析方法的经济高效替代方法。